0

GSK461364A

INQUIRY Add to cart
For Research Use Only | Not For Clinical Use
CATAP929095181
CAS929095-18-1
MDL NumberMFCD12755419
Molecular Weight543.60
Description≥98% (HPLC)
SolubilityDMSO: 25 mg/mL, clear
Assay≥98% (HPLC)
Colorwhite to beige
Formpowder
Size5MG, 25MG
Storage Conditions2-8°C
1

Current Clinical Trials With Polo-Like Kinase 1 Inhibitors in Solid Tumors

Hyungshin Yim

Anticancer Drugs. 2013 Nov;24(10):999-1006.

PMID: 23949254

1

Distinct Concentration-Dependent Effects of the Polo-Like Kinase 1-specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis

Aidan G Gilmartin, Maureen R Bleam, Mark C Richter, Symon G Erskine, Ryan G Kruger, Lenore Madden, Daniel F Hassler, Gary K Smith, Richard R Gontarek, Mary P Courtney, David Sutton, Melody A Diamond, Jeffrey R Jackson, etc.

Cancer Res. 2009 Sep 1;69(17):6969-77.

PMID: 19690138

1

GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM)

Praveena Velpurisiva, Brandon P Piel, Jack Lepine, Prakash Rai

Bioengineering (Basel). 2018 Oct 9;5(4):83.

PMID: 30304810

1

Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer

Fengyi Mao, Jie Li, Qian Luo, Ruixin Wang, Yifan Kong, Colin Carlock, Zian Liu, Bennet D Elzey, Xiaoqi Liu

Mol Cancer Ther. 2018 Jul;17(7):1554-1565.

PMID: 29716963

1

Synergistic Action of Gefitinib and GSK41364A Simultaneously Loaded in Ratiometrically-Engineered Polymeric Nanoparticles for Glioblastoma Multiforme

Praveena Velpurisiva, Prakash Rai

J Clin Med. 2019 Mar 15;8(3):367.

PMID: 30875975

  • Verification code
Contact Us

Send Us a Request

What is your specific need? We will do everything we can to meet your expectations.
Online Inquiry

Online Inquiry

For any inquiry, question or recommendation, please call: or fill out the following form.

  • Verification code

Head Office

  • Tel:
  • Email:

Follow us on

qrcode